Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The user is seeing positive results in hair growth using a combination of topical minoxidil, finasteride, microneedling, and keto shampoo. They also use a red light panel for collagen rebuilding and are happy with the progress.

The conversation is about a person's 3-month hair loss treatment using Minoxidil with crushed Finasteride tablets and weekly dermarolling. They shared their progress pictures.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The user experienced significant hair regrowth using 1mg finasteride and 2.5mg oral minoxidil, improving from NW5-6 to NW3-4 in three months. They plan to get a hair transplant in February and reported no side effects except increased body hair growth.

The conversation is about a user sharing their 3-month progress with finasteride, minoxidil, and weekly derma rolling for hair loss. Some suggest buzzing the hair off to better apply treatments and consider a hair transplant in the future.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

A 36-year-old has been using 5% Minoxidil for 3.5 months and is considering adding microneedling and PRP. Another user suggests adding finasteride and microneedling for better results.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

A 21-year-old male shares his 3-month progress using 0.5mg dutasteride daily, 5% topical minoxidil twice daily, and weekly microneedling, showing some temple recovery and seeking further improvement. Feedback suggests continued use and monitoring, with optimism for more regrowth over time.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

The user experienced hair regrowth and improved hair density using oral finasteride and topical minoxidil, with microneedling as an additional treatment. They are considering a hair transplant for low-density areas but are uncertain due to existing follicles.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The user shared a 3-month progress update on hair loss treatment using finasteride (1 mg), minoxidil (5% once or twice daily), and microneedling (1.5mm every 2 weeks) with no side effects. Commenters are impressed, discussing hair follicle revival and the user's method, noting the hair appears darker.

A user shared a 3-month progress update on using minoxidil and finasteride for hair regrowth, noting thicker hair. Replies included congratulations and advice on consistent lighting for photos.

Progress achieved with finasteride, oral minoxidil and derma rolling in the span of three months. The replies discussed potential regrowth from using these treatments as well as advised seeking professional medical help for further hair loss advice.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

User shared progress pictures after 3 months of using 1mg finasteride, 5% minoxidil, a dermaroller, and castor oil. They humorously commented on their results.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

The conversation is about an 18-year-old's progress with hair regrowth using oral Minoxidil, dermarolling, and RU58841 over three months, starting treatment after beginning to lose hair at 16. Participants are impressed with the improvement and encourage continued treatment.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.